Public Company Healthcare

BioLife Solutions

Bothell, Washington, United States

Preserving the Promise™. Developer and supplier of cell and gene therapy bioproduction tools, biopreservation consumables, cold-chain systems, freezers, and related services intended to protect the integrity of cells throughout production, storage, and delivery.

Focus Areas
Biopreservation, Cryopreservation solutions, Cold chain equipment

Tracked deals

3

3 tracked deals across 2020-2025.

Recent pace

0

0 tracked deals announced in the last 12 months.

Deal mix

Buyout

3 buyout

BioLife Solutions Acquisition Volume by Year

Last 3 years

Acquisition volume by year Annual acquisition counts for the last 3 years for BioLife Solutions. 1 2020 1 2021 1 2025

Supporting Data

Recent Transactions

  • BioLife Solutions Acquires PanTHERA CryoSolutions
    April 10, 2025
    Buyer
    BioLife Solutions, Inc.
    Target
    PanTHERA CryoSolutions, Inc.
    Seller
    PanTHERA CryoSolutions shareholders
    Industry
    Biotechnology
    Location
    Alberta, Canada
    Type
    Buyout

    BioLife Solutions acquired the remaining 90% of PanTHERA CryoSolutions for $9.3 million in cash plus 241,355 shares of BioLife common stock, with up to an additional $7.2 million of stock payable upon achievement of milestones. The acquisition adds PanTHERA's proprietary Ice Recrystallization Inhibitor (IRI) technology and scientific talent to BioLife's biopreservation consumables portfolio, accelerating product capability development for the cell and gene therapy market.

  • BioLife Solutions Acquires Stirling Ultracold
    March 22, 2021
    Buyer
    BioLife Solutions, Inc.
    Target
    Global Cooling, Inc. (operating as Stirling Ultracold)
    Seller
    Stirling shareholders
    Industry
    Manufacturing
    Location
    Ohio, United States
    Type
    Buyout

    BioLife Solutions, Inc. agreed to acquire Global Cooling, Inc., operating as Stirling Ultracold, in an all-stock merger in which BioLife will issue 6,646,870 shares to acquire 100% of Stirling. The deal (expected to close in early Q2 2021) expands BioLife's cold-chain and ULT freezer product portfolio, adds Stirling’s ~150 employees and IP, and is expected to be accretive on an adjusted net income per share basis in 2022 and beyond.

  • BioLife Solutions Acquires SciSafe
    September 21, 2020
    Buyer
    BioLife Solutions, Inc.
    Target
    SciSafe
    Seller
    SciSafe shareholders
    Industry
    Healthcare Services
    Location
    New Jersey, United States
    Type
    Buyout

    BioLife Solutions, Inc. (NASDAQ: BLFS) has entered into a definitive agreement to acquire SciSafe, a privately held multi-facility biostorage provider serving the cell and gene therapy and pharmaceutical industries. BioLife will pay $15 million cash and $15 million in newly issued BioLife common shares for 100% of SciSafe, with up to 626,000 additional shares earnable based on revenue milestones; the deal is expected to close on September 30.

Related Acquisition Pages

Biotechnology Buyers & Acquisitions 1 tracked deal by BioLife Solutions. Healthcare Services Buyers & Acquisitions 1 tracked deal by BioLife Solutions. Manufacturing Buyers & Acquisitions 1 tracked deal by BioLife Solutions. Acquisitions in New Jersey 1 tracked deal by BioLife Solutions. Acquisitions in Ohio 1 tracked deal by BioLife Solutions.

Selling a company? Get in front of buyers like BioLife Solutions

Turn tracked acquisition activity into an outreach-ready buyer list.

Find buyers like these →